Published • loading... • Updated
Iovance Faces Key Amtagvi Milestone as $101 Million Quarters Become Crucial for Stock
Summary by ts2.tech
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Iovance Faces Key Amtagvi Milestone as $101 Million Quarters Become Crucial for Stock
SAN CARLOS, California, August 15, 2026, 10:45 PDT The most recent session ended at $4.07, showing a 13.2% decrease. The full-year midpoint calls for about $101 million in revenue per quarter across the second half. Analyst price targets range from $2 to $14, indicating a rare degree of uncertainty around execution. Iovance Biotherapeutics (NASDAQ:IOVA) closed…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
